Mobidiag Launches High Throughput Microarray Platform with Triple Assay Content Capacity

Mobidiag’s new Prove-it™ StripArray platform enables greater assay content for new applications and improves throughput by automatic analysis of up to 96 patient samples in a single process

Helsinki, Finland 16 May – the Finnish biotech company Mobidiag announced today the new Prove-it™ StripArray platform, which provides high reliability and ease-of-use for the routine diagnostics users. Operating a series of samples on StripArray is faster and the semi-automated workflow reduces risk of human error. Compared to Mobidiag’s previous generation platform, Prove-it™ StripArray triples assay content capacity. This enables broader target panel. The wide-range platform provides high throughput for all Mobidiag’s current and future applications. In addition, it enables different applications to be united into one assay.

A compact instrument with a built-in computer and Prove-it™ Advisor software enables analysis and result reporting of 96 samples with virtually no hands-on-time. Furthermore, the software has tools for specific analysis of selected samples. The Prove-it™ Advisor for StripArray is a continuation of Mobidiag’s line of high quality software development as Microsoft Gold Certified Partner. Prove-it™ Advisor for StripArray is compatible with the TubeArray system which provides the customer an opportunity to use all Mobidiag’s test applications with the same instrument.

The applications for the StripArray are ideal in diagnostics requiring high throughput and cost-effectiveness. The StripArray platform was the key in extending the content of Prove-it™ Sepsis into a new application: the Prove-it™ Bone and Joint, and thus setting the new world record in bacterial identification with 64 targets. Prove-it™ StripArray will be available in June 2009.

Contact:
CEO Jaakko Pellosniemi, Mobidiag Ltd, tel. 358 40 501 1004, jaakko.pellosniemi@mobidiag.com

 
Mobidiag Ltd is a Finnish biotechnology company developing, producing and marketing rapid diagnostic tests to hospital laboratories. The company focuses on detection of serious infections with DNA-tests. More information at www.mobidiag.com.